Increased liver-related mortality to hepatitis C viremia defined on the 20th anniversary of its identification

Hepatology

Volumn 50, Issue 2, 2009, Pages 349-351

  Kenny Walsh, Elizabeth ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CAUSE OF DEATH; CHRONICITY; DEATH CERTIFICATE; DISEASE CARRIER; EDITORIAL; ENDEMIC DISEASE; HEPATITIS C; HUMAN; INCIDENCE; INTRAVENOUS DRUG ABUSE; MORBIDITY; MORTALITY; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; RISK FACTOR; VIREMIA; VIRUS TRANSMISSION; JAPAN; NOTE; VIROLOGY;

HEPATITIS C, CHRONIC; HUMANS; JAPAN; VIREMIA;

EID: 68949167577     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.23107     Document Type: Editorial

References (30)

1. Kim WR. Global epidemiology and burden of hepatitis C. Microbes Infect 2002;4:1219-1225.
2. Global surveillance and control of hepatitis C. Report of a WHO consultation organised in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999;6:35-47.
3. Perz J, Farrington L, Pecoraro C, Hutin YJF, Armstrong GL. Estimated global prevalence of hepatitis C virus infection. Presented at the 42nd annual meeting of the Infectious Diseases Society of America; September 30-October 3, 2004; Boston, MA.
4. Armstrong G, Alter M, McQuillan G, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. HEPATOLOGY 2000;31:777-782. (Pubitemid 30118650)
5. Centers for Disease Control and Prevention. Viral Hepatitis website. http://www.cdc.gov/ncidod/diseases/hepatitis/resource/PDFs/disease-burden2004. pdf. Accessed May 2009.
6. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993;328:1797-1801. (Pubitemid 23174709)
7. Tanaka Y, Kurbanov F, Mano S, Orito E, Vargas V, Esteban JI, et al. Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality. Gastroenterology 2006;130:703-714. (Pubitemid 43374521)
8. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRX, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-832. (Pubitemid 27129209)
9. European Association for the Study of the Liver International Consensus Conference on Hepatitis C. Consensus Statement. February 26-28, 1999; Paris, France. J Hepatol 1999;30:956-961.
10. Alter H, Conry-Cantalena C, Melpolder J. Hepatitis C in asymptomatic blood donors. HEPATOLOGY 1997;26(Suppl 1):29S-33S.
11. Seeff LB, Hollinger FB, Alter HJ, Wright EC, Cain CM, Buskell ZJ, et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: a National Heart, Lung, and Blood Institute collaborative study. HEPATOLOGY 2001;33:455-463.
12. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000;284:450-456. (Pubitemid 30484478)
13. Vogt M, Lang T, Frösner G, Klingler C, Sendl AF, Zeller A, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999;341:866-870. (Pubitemid 29427048)
14. Locasciulli A, Testa M, Pontisso P. Prevalence and natural history of hepatitis C infection in patients cured of childhood leukemia. Blood 1997;90:4628-4633. (Pubitemid 27508470)
15. Wiese M, Berr F, Lafrenz M, Porst H, Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single source outbreak in Germany: a 20-year multicenter study. HEPATOLOGY 2000;32:91-96.
16. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999;340:1228-1233.
17. Alter M, Kruszon-Moran D, Nainan O, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-562.
18. Nguyen GC, Thuluvath PJ. Racial disparity in liver disease: biological, cultural, or socioeconomic factors. HEPATOLOGY 2008;47:1058-1066.
19. Everhart J, Wei Y, Eng H, Charlton MR, Persing DH, Wiesner RH, et al. Recurrent and new hepatitis C virus infection after liver transplantation. HEPATOLOGY 1999;29:1220-1226. (Pubitemid 29168758)
20. Moucari R, Asselah T, Cazals-Hatem D, Voitot H, Boyer N, Ripault MP, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008;134:416-423. (Pubitemid 351181308)
21. Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. HEPATOLOGY 2001;34:809-816. (Pubitemid 32928008)
22. Seeff L. Natural history of chronic hepatitis C. HEPATOLOGY 2002;36(5 Suppl 1):S35-S46.
23. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-472. (Pubitemid 27078833)
24. Casiraghi MA, De Paschale M, Romano L, Biffi R, Assi A, Binelli G, et al. Long term outcomes (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth. HEPATOLOGY 2004;39:90-96. (Pubitemid 38461471)
25. Guiltinan AM, Kaidarova Z, Custer B, Orland J, Strollo A, Cyrus S, et al. Increased all-cause, liver, and cardiac mortality among hepatitis C virus-seropositive blood donors. Am J Epidemiol 2008;167:743-750.
26. Boschi-Pinto C, Stuver S, Okayama A, Trichopoulos D, Orav EJ, Tsubouchi H, et al. A follow-up study of morbidity and mortality associated with hepatitis C virus infection and its interaction with human T lymphotropic virus type I in Miyazaki, Japan. J Infect Dis 2000;181:35-41. (Pubitemid 30049030)
27. Amin J, Law MG, Bartlett M, Kaldor JM, Dore GJ, et al. Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet 2006;368:938-945.
28. Buti M, San Miguel R, Brosa M, Cabasés JM, Medina M, Angel Casado M, et al. Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C. J Hepatol 2005;42:639-645. (Pubitemid 40501679)
29. McHutchison JG, Bacon BR. Chronic hepatitis C: an age wave of disease burden. Am J Manag Care 2005;11:S286-S295. (Pubitemid 41552219)
30. Uto H, Stuver SO, Hayashi K, Kumagai K, Sasaki F, et al. Increased rate of death related to presence of viremia among hepatitis C virus antibody - positive subjects in a community-based cohort study. HEPATOLOGY 2009; doi:10.1002/hep.23002.